All results
13 results for breast cancer
-
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal…
- Ages
- 18 Years - N/A
- Sexes
- All
-
DoD Mastectomy
Breast cancer is the most common type of cancer in women. Removal of the breast, called "mastectomy", is performed either when there is cancer-or an increased…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will…
- Ages
- 18 Years - N/A
- Sexes
- All
-
ARGX-113-2007
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Compare Chemo Before and After Surgery vs After Surgery Alone for the TX of Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Study of XL092 in Comb. with Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Testing the Combination of ZEN-3694 and Talazoparib in Ps w/ Advanced Solid Tumors; ComBET
This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely…
- Ages
- 18 Years - N/A
- Sexes
- All
-
PAN009-18 (PC04): Protons for Unresectable, Borderline Resectable, or Medically Inoperable Panc
The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Phase 2 Study to evaluate Pembrolizumab Plus Lenvatinib in Combo w/ Belzutifan in Solid Tumors
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors…
- Ages
- 18 Years - N/A
- Sexes
- All